Tempus AI Price Target Cut and Buy Rating Maintained by Canaccord Genuity
Canaccord Genuity has lowered the price target for Tempus AI from $95.00 to $80.00 per share while maintaining a Buy rating on the stock. This indicates a revised valuation outlook but continued positive sentiment towards the company's prospects.
$Tempus AI(TEM)$$JPMorgan Chase(JPM)$ $NVIDIA(NVDA)$ 🧬📊 Tempus AI $TEM Pre-JPM Shock, 83% Revenue Surge, $1.1B Contracts and 126% Retention Tempus just delivered one of the most strategically powerful pre-announcements going into JPM Healthcare in years. $TEM pre-released Q4 revenue of approximately $367M versus $360M Street, confirming upside to near-term demand while positioning the company directly in front of the global healthcare buy side. That top-line acceleration is not cosmetic. Quarterly revenue rose ~83% year-over-year, driven by expanding adoption of Tempus’ AI-powered data, applications, and oncology intelligence platform. What t
$Tempus AI(TEM)$$JPMorgan Chase(JPM)$ $NVIDIA(NVDA)$ 🧬📊 Tempus AI $TEM Pre-JPM Shock, 83% Revenue Surge, $1.1B Contracts and 126% Retention Tempus just delivered one of the most strategically powerful pre-announcements going into JPM Healthcare in years. $TEM pre-released Q4 revenue of approximately $367M versus $360M Street, confirming upside to near-term demand while positioning the company directly in front of the global healthcare buy side. That top-line acceleration is not cosmetic. Quarterly revenue rose ~83% year-over-year, driven by expanding adoption of Tempus’ AI-powered data, applications, and oncology intelligence platform. What t